- ADMINISTRATION
- Formulation
SOMATULINE® DEPOT PROVIDES ONCE-MONTHLY DOSING VIA DEEP SUBCUTANEOUS INJECTION FROM A PREFILLED AND READY-TO-USE SYRINGE1,2
![Image](/sites/g/files/kcxpwu521/files/2023-06/formulation-01.png)
The formulation of Somatuline Depot enables steady release without the need for polymers or additives.2
![formulation-01.png](/sites/g/files/kcxpwu521/files/2023-06/formulation-01-e1573070445569.png)
High density of lanreotide nanotubes allows for low injection volume.2
![formulation-02.png](/sites/g/files/kcxpwu521/files/2023-06/formulation-02-e1573070467785.png)
Lanreotide is injected into the deep subcutaneous layer of the tissue. After injection, the formulation is thought to form a depot – or drug reservoir, for fast-acting (peak serum concentration of 7 hours) and sustained-release (half-life of 23 to 30 days) drug delivery.1,2
![formulation-03.png](/sites/g/files/kcxpwu521/files/2023-06/formulation-03-e1573070490677.png)
Lanreotide is slowly released, enabling delivery every 4 weeks.2
See the Pharmacokinetic profile of Somatuline Depot below
Discover more about the Somatuline Depot formulation and mechanism of action – watch now
Rapid onset of action and sustained-release formulation1,2
Somatuline Depot has been shown to reach peak serum concentration in 7 hours, followed by a steady and sustained release (half-life of 23 to 30 days)1,2
Serum concentrations achieved in healthy subjects following deep SC administration of Somatuline Depot2
![](/sites/g/files/kcxpwu521/files/2023-09/rapid-graph_0.png)
![image](/sites/g/files/kcxpwu521/files/2023-09/rapid-graph-mob.png)
SC=subcutaneous.
REFERENCES:
- Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2023.
- Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366-374.